BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial [Yahoo! Finance]
Brainstorm Cell Therapeutics Inc. (BCLI)
Last brainstorm cell therapeutics inc. earnings: 11/14 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.brainstorm-cell.com
Company Research
Source: Yahoo! Finance
neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS). This Type C meeting builds upon the positive momentum established in April 2024 , when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement for its NurOwn Phase 3b trial. The SPA agreement provided clarity on the design and endpoints of the trial, significantly de-risking the regulatory aspects of the program. "This in-person Type C meeting with the FDA was an important step as we finalize preparations for our pivotal Phase 3b trial of NurOwn. We are very pleased with the outcome and are now aligned with the FDA on resolving all previously outstanding CMC questions," said Chaim Lebovits , President & Chief Executive Officer of BrainStorm. "As with any cell therapy pr
Show less
Read more
Impact Snapshot
Event Time:
BCLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCLI alerts
High impacting Brainstorm Cell Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCLI
News
- BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct OfferingPR Newswire
- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical TrialPR Newswire
- BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer [Yahoo! Finance]Yahoo! Finance
BCLI
Earnings
- 11/14/23 - Beat
BCLI
Sec Filings
- 6/28/24 - Form 424B5
- 6/28/24 - Form 8-K
- 6/27/24 - Form 424B5
- BCLI's page on the SEC website